Overview

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

Status:
Terminated
Trial end date:
2017-09-29
Target enrollment:
0
Participant gender:
All
Summary
THIS IS THE SECOND PART OF A 2-PART STUDY. The purpose of the first part of this study was to determine the safety and tolerability of ascending doses of valproic acid (also known as Depacon) administered as intravenous infusion (IV) in doses ranging from 15 mg/kg to 250 mg/kg in healthy subjects. ID: VPA-C-002 The second part of the study will also be to determine the safety and tolerability of single ascending doses of valproic acid administered as IV in trauma subjects with hemorrhagic shock.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Dr. Hasan Alam
Treatments:
Valproic Acid
Criteria
Inclusion Criteria:

1. Male and non-pregnant female trauma patients between the ages of 18-70 years,
inclusive.

2. Blunt or penetrating trauma resulting in two or more systolic blood pressure readings
of ≤ 110 mmHg at any point during transport to the hospital or within the first hour
after arrival in the emergency department. Systolic blood pressure readings of ≤ 110
mmHg need not be consecutive (Eastridge et al., 2007).

3. Patient's admission to the emergency department results in trauma team activation (per
institutional criteria, see Appendix 7).

4. Patient's injuries are considered potentially survivable by the attending trauma
surgeon on initial evaluation.

5. Able to provide informed consent or consent can be obtained from a representative
(spouse or other legally authorized representative) in the event that the subject is
unconscious or otherwise impaired.

6. Female subjects must be postmenopausal, surgically sterilized, or have a negative
urinary pregnancy test on arrival. Criteria for menopause include age > 45 with
absence of menses for > 12 months. Criteria for surgical sterilization include
hysterectomy and/or oophorectomy. Tubal ligation with menses within the past 12 months
is not considered to be surgical sterilization.

7. Body mass index (BMI) between 18 kg/m2 and 35 kg/m2

Exclusion Criteria:

1. Subjects with known history of adverse reaction to Valproic acid.

2. Subjects with known history of hepatitis B or C or clinical history of hepatic
dysfunction, pancreatitis, or renal insufficiency.

3. Subjects with -amylase >400 U/L or lipase >300 U/L or creatinine >ULN

4. Subjects with AST or ALT >3X Upper limit of normal (ULN) or total bilirubin >1.5X
Upper limit of normal (ULN)

5. Subjects with 2nd or 3rd degree burns of any size and location.

6. Female subjects who are pregnant or lactating.

7. Subjects who are currently incarcerated.

8. Subjects with severe traumatic brain injury (with Glasgow Coma Scale score <8 on
arrival to the emergency department).

9. Non-hemorrhagic causes of shock, including septic, cardiogenic, or neurogenic shock or
mechanical reasons such as tension pneumothorax or cardiac temponade.

10. Subjects with inadequate venous access.

11. Subject with a hemoglobin level of less than 8g/dL.

-